Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms

Abhishek Chandra, Tiao Lin, Tiffany Young, Wei Tong, Xiaoyuan Ma, Wei Ju Tseng, Ina Kramer, Michaela Kneissel, Michael A. Levine, Yejia Zhang, Keith Cengel, X. Sherry Liu, Ling Qin

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/β-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/β-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. Micro-CT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of γ-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment.

Original languageEnglish (US)
Pages (from-to)360-372
Number of pages13
JournalJournal of Bone and Mineral Research
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Stem Cells
Radiation
Bone and Bones
Osteocytes
Osteoblasts
DNA Repair
Apoptosis
Osteoporosis
Catenins
Radiotherapy
Therapeutics
Wnt Signaling Pathway
Double-Stranded DNA Breaks
Adipocytes
DNA Damage
Bone Marrow
Monoclonal Antibodies

Keywords

  • DNA REPAIR
  • MESENCHYMAL PROGENITORS
  • OSTEOBLASTS
  • RADIOTHERAPY
  • SCL-AB

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. / Chandra, Abhishek; Lin, Tiao; Young, Tiffany; Tong, Wei; Ma, Xiaoyuan; Tseng, Wei Ju; Kramer, Ina; Kneissel, Michaela; Levine, Michael A.; Zhang, Yejia; Cengel, Keith; Liu, X. Sherry; Qin, Ling.

In: Journal of Bone and Mineral Research, Vol. 32, No. 2, 01.02.2017, p. 360-372.

Research output: Contribution to journalArticle

Chandra, A, Lin, T, Young, T, Tong, W, Ma, X, Tseng, WJ, Kramer, I, Kneissel, M, Levine, MA, Zhang, Y, Cengel, K, Liu, XS & Qin, L 2017, 'Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms', Journal of Bone and Mineral Research, vol. 32, no. 2, pp. 360-372. https://doi.org/10.1002/jbmr.2996
Chandra, Abhishek ; Lin, Tiao ; Young, Tiffany ; Tong, Wei ; Ma, Xiaoyuan ; Tseng, Wei Ju ; Kramer, Ina ; Kneissel, Michaela ; Levine, Michael A. ; Zhang, Yejia ; Cengel, Keith ; Liu, X. Sherry ; Qin, Ling. / Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. In: Journal of Bone and Mineral Research. 2017 ; Vol. 32, No. 2. pp. 360-372.
@article{ef4902d02b0c479a9fc81912db5aa323,
title = "Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms",
abstract = "Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/β-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/β-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. Micro-CT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of γ-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment.",
keywords = "DNA REPAIR, MESENCHYMAL PROGENITORS, OSTEOBLASTS, RADIOTHERAPY, SCL-AB",
author = "Abhishek Chandra and Tiao Lin and Tiffany Young and Wei Tong and Xiaoyuan Ma and Tseng, {Wei Ju} and Ina Kramer and Michaela Kneissel and Levine, {Michael A.} and Yejia Zhang and Keith Cengel and Liu, {X. Sherry} and Ling Qin",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/jbmr.2996",
language = "English (US)",
volume = "32",
pages = "360--372",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms

AU - Chandra, Abhishek

AU - Lin, Tiao

AU - Young, Tiffany

AU - Tong, Wei

AU - Ma, Xiaoyuan

AU - Tseng, Wei Ju

AU - Kramer, Ina

AU - Kneissel, Michaela

AU - Levine, Michael A.

AU - Zhang, Yejia

AU - Cengel, Keith

AU - Liu, X. Sherry

AU - Qin, Ling

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/β-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/β-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. Micro-CT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of γ-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment.

AB - Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/β-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/β-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. Micro-CT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of γ-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment.

KW - DNA REPAIR

KW - MESENCHYMAL PROGENITORS

KW - OSTEOBLASTS

KW - RADIOTHERAPY

KW - SCL-AB

UR - http://www.scopus.com/inward/record.url?scp=84991759884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991759884&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2996

DO - 10.1002/jbmr.2996

M3 - Article

C2 - 27635523

AN - SCOPUS:84991759884

VL - 32

SP - 360

EP - 372

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -